Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention
Isis Koutrouli, Vojtěch Brejtr, Marek Schwendt, Kacper Witek, Chrysostomos Charalambous, K. Aleksič, N. Miniariková, Eva Lhotková, Martin Toman, Marek Nikolič, Radek Jurok, Petra Cihlářová, Vladimír Mazoch, Pavel Ryšánek, Martin Kuchař, Klára Šíchová, Tomáš Páleníček
Addiction Biology March 1, 2026 DOI: 10.1111/adb.70111 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical experimental study Randomized Peer reviewed |
|---|---|
| Population | Wistar male rats |
| Interventions | Psilocybin Ibogaine |
| Dose | 1.25 mg/kg and 5 mg/kg psilocybin; 10 mg/kg and 40 mg/kg ibogaine |
| Duration | 10-day extinction period with treatments on days 1 and 5; cue-induced reinstatement test 6 days after last treatment |
| Topics | Psilocybin Ibogaine |
| Keywords | Extinction optical mineralogy Hallucinogen Drug Open field Pharmacology |
| Key findings | Psilocybin and ibogaine facilitated extinction learning in male rats after cocaine self-administration, but neither significantly reduced cue-induced reinstatement. |
Abstract
Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Here, we investigated the effects of a clinically inspired dose-escalation protocol of psilocybin and ibogaine on extinction and cue-induced reinstatement in Wistar male rats following intravenous cocaine self-administration (IVSA). Rats were trained on a fixed ratio 1 (FR1) schedule with cocaine dose-escalation during the acquisition phase (0.25 mg/kg/infusion, followed by 0.5 mg/kg/infusion). Following acquisition, animals were randomised into treatment groups and then subjected to 10 days of extinction. Psilocybin (1.25 mg/kg and 5 mg/kg) or ibogaine (10 mg/kg and 40 mg/kg) was administered subcutaneously and intraperitoneally, respectively, on extinction days 1 and 5. A cue-induced reinstatement test was conducted 6 days after the last treatment. Both treatments significantly modulated behaviour during extinction; psilocybin reduced active lever pressing 1 day after the second dose, with a nonsignificant reduction already apparent after the first dose, while the effect of ibogaine was significant even after the first administration. However, neither compound significantly altered reinstatement behaviour, although psilocybin showed a trend toward attenuation. The applied treatment had no side effects on general locomotor activity or anxiety-like behaviour, as measured in the open field test 24 h after each administration. These findings support a role for psilocybin and ibogaine in facilitating extinction learning and suggest possible protective effects against relapse, warranting further research into their antiaddictive efficacy.